Insider · CIK 0001053890
Raymond Debbane
Files at LXRX (LEXICON PHARMACEUTICALS, INC.). First filing Feb 18, 2026, latest Feb 27, 2026.
Raymond Debbane files SEC Form 4 as 10% owner and director at LXRX (LEXICON PHARMACEUTICALS, INC.). Since Feb 18, 2026, Raymond Debbane has reported 4 open-market buys worth $723k and 0 open-market sells worth $0, the latest filed on Feb 27, 2026.
A track record needs three past buys with six months of prices behind them; Raymond Debbane has 0, so none is measured yet.
The newest scored trade: bought $2,980 of LXRX on Feb 25, 2026, filed Feb 27, 2026, scored 15 (weak). In the last 12 months: 4 buys worth $723k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
LXRX: LEXICON PHARMACEUTICALS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | LXRXbuy LEXICON PHARMACEUTICALS, INC. | $2,980 2,000 shares | +0% | - | |
| 34Weak | LXRXbuy LEXICON PHARMACEUTICALS, INC. | $147k 100,000 shares | +6% | - | |
| 35Weak | LXRXbuy LEXICON PHARMACEUTICALS, INC. | $220k 150,000 shares | +9% | - | |
| 41Moderate | LEXICON PHARMACEUTICALS, INC. | $353k 268,497 shares | +19% | - |
Transactions
Every row this insider has filed, 15 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +89,312 | $0.00 | $0 | 1,995,498 | Jun 4, 2026 |
| Jun 3, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -89,312 | $0.00 | $0 | 0 | Jun 4, 2026 |
| May 1, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitsderivative | +35,714 | $0.00 | $0 | 35,714 | May 4, 2026 |
| May 1, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +43,478 | $0.00 | $0 | 43,478 | May 4, 2026 |
| Feb 25, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | POpen-market purchase Common Stock | +2,000 | $1.49 | $2,980 | 1,906,186 | Feb 27, 2026 |
| Feb 23, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | POpen-market purchase Common Stock | +100,000 | $1.47 | $147k | 1,904,186 | Feb 25, 2026 |
| Feb 19, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | POpen-market purchase Common Stock | +50,000 | $1.44 | $72k | 1,704,186 | Feb 23, 2026 |
| Feb 20, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | POpen-market purchase Common Stock | +100,000 | $1.48 | $148k | 1,804,186 | Feb 23, 2026 |
| Feb 13, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | POpen-market purchase Common Stock | +57,952 | $1.31 | $76k | 1,443,641 | Feb 18, 2026 |
| Feb 17, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | POpen-market purchase Common Stock | +76,857 | $1.31 | $101k | 1,520,498 | Feb 18, 2026 |
| Feb 18, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | POpen-market purchase Common Stock | +133,688 | $1.32 | $176k | 1,654,186 | Feb 18, 2026 |
| Jun 3, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +103,806 | $0.00 | $0 | 103,806 | Jun 3, 2025 |
| Jun 3, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitsderivative | +89,312 | $0.00 | $0 | 89,312 | Jun 3, 2025 |
| May 13, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +36,810 | $0.00 | $0 | 1,385,689 | May 13, 2025 |
| May 13, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -36,810 | $0.00 | $0 | 0 | May 13, 2025 |
Questions about Raymond Debbane
Answered from the filings on this page, as of the latest one.
Is Raymond Debbane buying or selling?
In the last 12 months Raymond Debbane reported 4 open-market buys worth $723k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $2,980 of LXRX on Feb 25, 2026. Grants, option exercises and tax withholding are not counted.
How did Raymond Debbane's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Raymond Debbane has 0.
Where does Raymond Debbane file Form 4?
Raymond Debbane has filed Form 4 at LXRX (LEXICON PHARMACEUTICALS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.